During the 83rd Annual Scientific Meeting of the American College of Gastroenterology, researchers from the United Kingdom reported on yet another large, nonmedical switch from reference infliximab to biosimilar CT-P13 (Inflectra, Remsima), this time in the Pennine Acute Hospitals Trust.
In the United Kingdom, where switching patients to biosimilars has become more common as National Health Service trusts seek to benefit from cost savings, multiple reports have noted the feasibility of switching patients to biosimilar infliximab.
During the 83rd Annual Scientific Meeting of the American College of Gastroenterology, researchers from the United Kingdom reported on yet another large, nonmedical switch from reference infliximab to biosimilar CT-P13 (Inflectra, Remsima), this time in the Pennine Acute Hospitals Trust.
The research team, led by Anirudh Pramod Bhandare, MBBS, MD, performed a retrospective review of patients with inflammatory bowel disease who were switched from the reference product to the biosimilar, and analyzed disease demographics, the clinical course of disease, and outcomes until the time of the last follow-up.
In total, 96 patients were switched, 44 of whom had ulcerative colitis (UC) and 52 of whom had Crohn disease (CD). The mean age at diagnosis was 34.73 years. The mean duration of treatment with the reference was 49.8 months, and the mean duration of treatment with the biosimilar at the time of the review was 7.9 months.
At the time of the switch, 76 patients had normal C-reactive protein (CRP) levels, while 15 patients had elevated levels. At follow-up, 14 patients had an increase in CRP. Eighty patients remained in biochemical remission.
In 31 patients, therapeutic drug monitoring was performed. In 28 patients, infliximab was maintained in the therapeutic range, while 3 patients required dose intensification.
At the time of the last follow-up, 72 patients (34 with UC and 38 with CD) were in clinical remission, and 31 patients (13 with UC and 18 with CD) had achieved mucosal healing.
The investigators concluded that biosimilar infliximab was well tolerated and maintained efficacy in patients who switched, which indicates that switching can “fulfill the purported aims of improving access to treatment and reducing costs.”
Reference
Bhandare AP, Nigam GB, Nayeemudin S, Limdi JK. Efficacy and tolerability of a biosimilar infliximab switch—a large single-centre experience from the U.K. Presented at the 83rd Annual Scientific Meeting of the American College of Gastroenterology, October 5-10, 2018; Philadelphia, Pennsylvania. Abstract 676. https://www.nature.com/articles/s41395-018-0296-0.pdf.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar and Biologic Use Increasing in Greek Patients With IBD
April 19th 2025A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.